| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Prelude Therapeutics Incorporated$4.81
-0.11 (-2.14%)
D 39Pipeline Score Fair Value Biotech · Commercial
Market Cap
340.09 M
EPS
-1.06
P/E Ratio
-
Value Trade
1.36 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
4.58 M
R&D Expenses
13.60 M
Operating CF
-21.68 M
Total Assets
119.64 M
Total Liabilities
59.46 M
Equity
60.18 M
D/E Ratio
12,345
-1.39 %
Week
-8.37 %
1 Month
88.94 %
3 Month
165.22 %
6 Month
-89.15 %
5 Year
-83.08 %
All Time
Cash Data
Cash Position
81.55 M
Monthly Burn
7.23 M
Runway
9.6 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
577.89 K
52 Week Range
0.75 - 5.54
% held by Insiders
47.57 %
% held by Institutions
33.32 %
Enterprise Value
276.25 M
Total Shares
43.72 M
Short %
16.55 %
Float Shares
17.05 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Prelude Therapeutics Incorporated
386Total events
4Upcoming
65Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 4
Event history 382
Q3 2026
●Trial InitiationPRT13722Trial
Phase 1 study initiation planned in 2H 2026
HR+/HER2- breast cancersource ↗
Q3 2026
◆Trial InitiationTrial
Phase 1 dose escalation study for KAT6A degrader expected to initiate in second half of 2026
ER+ breast cancersource ↗
Jun 10, 2026
●Oral PresentationPresentation
Fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference
Jun 3, 2026
Jun 2026
Jun 2026
May 12, 2026
▲First Patient DosedPRT12396Trial
Initiated enrollment of Phase 1 study of PRT12396 in PV and MF
polycythemia vera (PV) and myelofibrosis (MF)source ↗
May 12, 2026
Apr 21, 2026
◆Poster PresentationPRT13722Presentation
Poster presentation of preclinical data for PRT13722 at AACR 2026
HR+/HER2- breast cancersource ↗
Apr 20, 2026
▼Equity OfferingCorporate
Pricing of $90.0 million underwritten offering of common stock and pre-funded warrants
Apr 20, 2026
Drug Pipeline Intelligence
D39
Pipeline Score $271M
Pipeline ValueFair Value
Valuation Signal7
Drugs Scored2.7x
rNPV / MCap Top 55%
Micro Cap (rank 411 of 911)
Percentile RankPrelude Therapeutics Incorporated faces pipeline headwinds (39/100), with $1.9B risk-adjusted pipeline value, led by PRT3789 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRT3789 Small molecule | Advanced Solid Tumor | Phase 1 | NCT05639751 | 5% | $1.6B | COMPLETED | 135 | - | - | Oct 1, 2025 | - | Oct 16, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PRT3789 | patients with advanced solid tumors with loss of SMARCA4 | Phase 1/2 | 2025-04-25 | SMARCA2 resynthesis rate is 2-3 times slower than SMARCA4 thereby enhancing the selectivity profile and contributing to the broad therapeutic index and favorable safety profile observed with PRT3789 in clinical studies to date. Read More | Investor Contact: Robert A. Doody, Jr. Senior Vice President, Investor Relations Prelude Therapeutics Incorporated 484.639.7235 rdoody@preludetx.com Read More | |
PRT3789 | patients with advanced solid tumors with loss of SMARCA4 | Phase 1/2 | 2025-04-25 | SMARCA2 resynthesis rate is 2-3 times slower than SMARCA4 thereby enhancing the selectivity profile and contributing to the broad therapeutic index and favorable safety profile observed with PRT3789 in clinical studies to date. Read More | Investor Contact: Robert A. Doody, Jr. Senior Vice President, Investor Relations Prelude Therapeutics Incorporated 484.639.7235 rdoody@preludetx.com Read More | |
PRT3789 | patients with advanced solid tumors with loss of SMARCA4 | Phase 1/2 | 2025-04-25 | SMARCA2 resynthesis rate is 2-3 times slower than SMARCA4 thereby enhancing the selectivity profile and contributing to the broad therapeutic index and favorable safety profile observed with PRT3789 in clinical studies to date. Read More | Investor Contact: Robert A. Doody, Jr. Senior Vice President, Investor Relations Prelude Therapeutics Incorporated 484.639.7235 rdoody@preludetx.com Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PRLD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PRLD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PRLDPrelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Prelude Therapeutics reported its financial results for Q1 2026 and shared several updates on its research and development pipeline. The company initiated enrollment for the Phase 1 study of its mutant-selective JAK2V617F inhibitor, PRT12396, and plans to file an IND application for PRT13722, a KAT6A degrader, in mid-2026. Prelude also reported a cash runway extended into the second quarter of 2028 following a successful $90 million capital raise, and appointed a new Chief Medical Officer, Charles Morris, M.D. These developments reflect the company's focus on advancing its oncology pipeline amidst operational changes.
Read more →PRLDBALANCE SHEETS (in thousands, except share data)
Prelude Therapeutics has reported its financial results for Q1 2026 and provided updates on its research and development pipeline. The company has initiated enrollment in a Phase 1 study for PRT12396, a mutant-selective JAK2V617F inhibitor, and anticipates a mid-2026 IND filing for PRT13722, aimed at ER+ breast cancer treatment. Prelude aims to leverage a substantial cash runway expected to last until mid-2028, signaling a potential for ongoing development despite a reported net loss.
Read more →PRLDPrelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
Prelude Therapeutics has announced the pricing of an underwritten offering, raising approximately $90 million through the sale of shares and pre-funded warrants. The offering, led by RA Capital Management, is expected to close on April 21, 2026. The funds will primarily be used for general corporate purposes, including research and development of its oncology products.
Read more →PRLDPrelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Prelude Therapeutics presented promising preclinical data for PRT13722, a first-in-class KAT6A degrader, at the AACR Annual Meeting 2026. The data indicate its potential for complete tumor regressions in HR+/HER2- breast cancer models, with an improved safety profile. The company plans to file an IND application by mid-2026 and initiate clinical trials in the second half of 2026.
Read more →PRLDFirst-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved preclinical hematological safety profile
PRT13722, a first-in-class oral KAT6A degrader, has demonstrated the ability to drive complete tumor regressions in preclinical studies. Additionally, it showcases an improved safety profile concerning hematological effects. This development positions PRT13722 as a promising candidate in cancer therapy.
Read more →PRLD▲ +20.8%on this newsshared move
Beyond Conventional Payloads: Unlocking New Therapeutic Landscapes With Precision Degrader-Antibody Conjugates (DACs)
The article discusses the development of Precision Degrader-Antibody Conjugates (DACs) by Prelude Therapeutics. These innovative therapies aim to enhance treatment efficacy by targeting specific disease mechanisms. The approach represents a significant advancement in biopharmaceuticals, potentially leading to better patient outcomes in various conditions.
Read more →PRLD▲ +25.5%on this newsshared move
selective KAT6A degraders and JAK2V617F mutant selective inhibitors -- new approaches to clinically validated targets with transformative potential for patients. Prelude Therapeutics is leveraging its expertise in target
Prelude Therapeutics has appointed Dr. Charles Morris as Chief Medical Officer, effective April 20, 2026. With over 30 years of oncology drug development experience, Dr. Morris will lead the company's efforts as it advances its clinical programs targeting myeloproliferative neoplasms and ER+ breast cancer, expected to enter clinical development in 2026. His expertise is seen as crucial for the execution of Prelude's innovative cancer therapies, which aim to address significant unmet needs in the patient community.
Read more →PRLD▲ +25.5%on this newsshared move
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
Prelude Therapeutics has appointed Dr. Charles Morris as Chief Medical Officer, effective April 20, 2026. Dr. Morris, who has over 30 years of experience in oncology drug development, will oversee the company's lead programs targeting myeloproliferative neoplasms and ER+ breast cancer. His expertise is anticipated to significantly contribute to Prelude's strategic goals in advancing its innovative pipeline.
Read more →PRLD▼ -9%on this news
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Prelude Therapeutics announced that their oral KAT6A selective degrader, PRT13722, has been accepted for presentation at the AACR Annual Meeting 2026. The company aims to demonstrate the drug's potential for treating ER+ breast cancer with improved efficacy and safety. An IND filing is expected mid-2026, with clinical trials planned for later that year.
Read more →PRLDDiscovery of precision degrader antibody conjugates (pDACs) employing novel SMARCA2/4 degrader payloads
The article discusses the discovery of precision degrader antibody conjugates (pDACs) utilizing novel SMARCA2/4 degrader payloads. This development is part of Prelude Therapeutics' ongoing research efforts in targeted therapies. The focus is on advancing their pipeline and enhancing treatment options for specific cancer types.
Read more →PRLD▲ +16.5%on this news
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Prelude Therapeutics reported its financial results for the full year 2025, highlighting FDA clearance of its Investigational New Drug application for PRT12396 and plans to initiate Phase 1 studies for both PRT12396 and PRT13722 in 2026. The company emphasized its focus on developing mutant-selective inhibitors and KAT6A degraders while maintaining a cash runway expected to last into mid-2027. Despite a net loss of $99.5 million, Prelude believes its innovative approaches could significantly benefit patients with specific cancer targets.
Read more →PRLD▲ +16.5%on this news
PRELUDE THERAPEUTICS INCORPORATED BALANCE SHEETS December 31, (in thousands, except share and per share data) 2025 2024 Assets Current assets: Cash and cash equivalents $ 35,256 $ 12,474 Marketable securities 67,958 121,
Prelude Therapeutics reported its financial results for the full year 2025 and provided an outlook for 2026, highlighting significant advancements in its drug development pipeline. The company received FDA clearance for its IND application for PRT12396 and anticipates initiating its Phase 1 study in high-risk patients by Q2 2026. Prelude's financial position remains robust with $106 million in cash and equivalents, sufficient to fund operations into the second quarter of 2027. Despite losses reported, the company is optimistic about the potential impact of its mutant-selective therapies for cancer treatment.
Read more →PRLDPrelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Prelude Therapeutics has received FDA clearance for its Investigational New Drug Application for PRT12396, a mutant-selective JAK2V617F inhibitor. The Phase 1 study is set to begin by Q2 2026, focusing on patients with polycythemia vera and myelofibrosis. This development is seen as a pivotal step in advancing their oncology programs.
Read more →PRLD▲ +12.8%on this newsshared move
Investor Contact: Robert A. Doody, Jr. Senior Vice President, Investor Relations Prelude Therapeutics Incorporated 484.639.7235 rdoody@preludetx.com
Prelude Therapeutics announced FDA clearance of its IND for PRT12396, a JAK2V617F inhibitor aimed at treating myeloproliferative neoplasms. The Phase 1 study is expected to begin by Q2 2026, focusing on patients with polycythemia vera and myelofibrosis. This clearance marks a key milestone for the company, highlighting its commitment to innovative treatments in precision oncology. Prelude aims to explore the drug's safety and efficacy in the upcoming trial, which could significantly impact treatment outcomes for patients.
Read more →PRLDThis presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited t
Prelude Therapeutics has provided a corporate presentation outlining its forward-looking statements and anticipated developments in its clinical programs. The focus is on two primary candidates targeting the JAK2V617F mutation in myeloproliferative neoplasms and KAT6A selective degraders for breast cancer. The detailed milestones for these programs and the strategic insights from the leadership team highlight the company's commitment to advancing precision medicine. However, no specific negative events were reported in this presentation.
Read more →PRLDPrelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
Prelude Therapeutics presented promising preclinical data on its JAK2V617F-selective JH2 inhibitor, PRT12396, at the ASH Annual Meeting. The data suggests potential for disease modification in myeloproliferative neoplasms (MPNs). Additionally, the company disclosed a novel mCALR-targeted degrader antibody conjugate. Prelude plans to file for IND in early 2026, aiming to advance both programs into clinical trials.
Read more →PRLDDiscovery of First-in-Class Calreticulin-targeted Degrader Antibody Conjugates Delivering a CDK9 Degrader Payload for the Treatment of CALR-mutated MPNs
The article discusses the discovery of a novel therapy targeting calreticulin for treating CALR-mutated myeloproliferative neoplasms (MPNs). This first-in-class calreticulin-targeted degrader antibody conjugate delivers a CDK9 degrader payload, potentially enhancing treatment efficacy. The innovative approach may lead to significant advancements in managing these conditions.
Read more →PRLDDiscovery and preclinical characterization of orally bioavailable JAK2V617F mutant selective JH2 inhibitors with disease modification potential in myeloproliferative neoplasms
The article discusses the discovery and preclinical evaluation of novel JH2 inhibitors that selectively target the JAK2V617F mutant. These compounds exhibit potential for disease modification in myeloproliferative neoplasms and are designed to be orally bioavailable, which could enhance patient adherence to treatment. The research highlights the significance of these inhibitors in advancing therapeutic options.
Read more →PRLD▲ +8.9%on this news· ran to +22% by day 3
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Prelude Therapeutics reported its Q3 2025 financial results, highlighting advancements in its JAK2V617F inhibitor and KAT6A degrader programs. The company expects to file INDs for both programs in 2026. Prelude also announced a strong cash position, projecting funding into 2027, despite reporting a net loss of $19.7 million for the quarter. Key preclinical data will be presented at the upcoming ASH meeting.
Read more →PRLD▲ +8.9%on this news· ran to +22% by day 3shared move
PRELUDE THERAPEUTICS INCORPORATED BALANCE SHEETS (in thousands, except share data)
Prelude Therapeutics has reported its third-quarter financial results for 2025, highlighting key advancements in its drug development pipeline. The company is actively progressing with its lead candidates for JAK2V617F JH2 inhibitor and KAT6A selective degrader, with anticipated IND filings in 2026. Furthermore, preclinical data from these programs have been accepted for presentation at the upcoming American Society of Hematology annual meeting. Despite a reported loss of $19.7 million for the quarter, Prelude expects its current financial resources to support operations into 2027.
Read more →PRLD▼ -55.8%on this news· ran to -70% by day 3
Prelude Therapeutics Announces Strategic Business Update
Prelude Therapeutics has announced a strategic update focusing on the development of its JAK2V617F inhibitor and KAT6A degrader programs while pausing its SMARCA2 program. The company has secured an option agreement with Incyte, which includes a $35 million upfront payment and potential future funding. Prelude aims to advance its KAT6A program into clinical development by 2026, with expectations of extending its cash runway into 2028 if Incyte exercises its option.
Read more →PRLD▼ -55.8%on this news· ran to -70% by day 3shared move
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Prelude Therapeutics has entered into an exclusive option agreement with Incyte for its JAK2V617F JH2 inhibitor program, aimed at treating myeloproliferative neoplasms. Prelude will receive $35 million upfront, along with a $25 million equity investment, and potential future payments totaling up to $910 million. Incyte will lead development if the option is exercised, while Prelude continues to develop its assets during the option period.
Read more →PRLD▲ +131.4%on this newsshared move
Sri Sahasranaman, Ph.D.
Sri Sahasranaman has been appointed as Senior Vice President of Clinical Pharmacology at Prelude Therapeutics. He brings over 20 years of experience in drug development, having previously built the Global Clinical Pharmacology organization at BeiGene. His extensive background includes leadership roles at Genentech, Novartis, and Sanofi, with a focus on oncology and innovative dose optimization.
Read more →PRLD▲ +150.3%on this newsshared move
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
Prelude Therapeutics announced the acceptance of two abstracts for oral presentation at the ASH 67th Annual Meeting. The abstracts detail preclinical data on their JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates. These discoveries aim to provide novel treatment options for patients with myeloproliferative neoplasms (MPNs).
Read more →PRLD▼ -9.2%on this news· ran to +21% by day 3
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
Prelude Therapeutics has appointed Katina Dorton to its Board of Directors, effective immediately. Dorton, who has over 30 years of experience in healthcare and life sciences, will also serve as Audit Committee Chair. She succeeds Mardi C. Dier, who is resigning from the board. Prelude aims to leverage Dorton's expertise to advance its precision oncology initiatives.
Read more →PRLDPrelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Prelude Therapeutics reported its financial results for Q2 2025 and provided updates on its clinical development pipeline. The company is advancing PRT7732, an oral SMARCA2 degrader, while pausing development on PRT3789. Prelude expects to report preliminary clinical data for PRT7732 by the end of 2025 and is on track to file an IND for its KAT6A degrader program in the first half of 2026. Financially, Prelude reported a decrease in R&D and G&A expenses and maintains sufficient cash reserves until mid-2026.
Read more →PRLD▼ -7.2%on this news
A Phase 1 Study of PRT2527, a Selective CDK9 Inhibitor, as Monotherapy and in Combination With Zanubrutinib in Relapsed / Refractory Lymphoid Malignancies: Updated Analysis
The article discusses an updated analysis of a Phase 1 study evaluating PRT2527, a selective CDK9 inhibitor, both as a standalone treatment and in combination with zanubrutinib for patients with relapsed or refractory lymphoid malignancies. The study aims to assess the safety and efficacy of these treatment options. Initial findings suggest a positive outlook for PRT2527 in this patient population.
Read more →PRLD▼ -7.2%on this news
Discovery of First-in-Class Precision Antibody Drug Conjugates Targeting Mutant Calreticulin For the Treatment of Myeloproliferative Neoplasms
The article discusses the discovery of a novel class of precision antibody drug conjugates aimed at treating myeloproliferative neoplasms by targeting mutant calreticulin. This innovative approach could lead to significant advancements in patient care and treatment efficacy. The research team includes a diverse group of scientists and experts in the field.
Read more →PRLDPrelude Therapeutics to Participate in Upcoming Healthcare Conferences
Prelude Therapeutics will participate in two upcoming healthcare conferences in June 2025. CEO Kris Vaddi will engage in fireside chats at the Jefferies Global Healthcare Conference on June 5 and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11. Live webcasts will be available on the company's website.
Read more →PRLDA Phase 2 Safety and Efficacy Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors and a SMARCA4 Mutation
The article discusses a Phase 2 study evaluating the safety and efficacy of PRT3789 in combination with pembrolizumab for patients with advanced or metastatic solid tumors harboring a SMARCA4 mutation. This study aims to explore new treatment avenues for this specific group of cancer patients. The trial is led by a team of experienced oncologists and researchers.
Read more →PRLDPrelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Prelude Therapeutics has reported its financial results for Q1 2025, showcasing a cash runway extending into Q2 2026 supported by $103.1 million. The company is advancing its clinical studies, including PRT3789 and PRT7732, with updates expected in the latter half of 2025. CEO Kris Vaddi emphasized significant progress in their oncology pipeline and presented preclinical data for other candidates at recent conferences. However, the company also noted a net loss of $32.1 million and rising R&D expenses, which may raise concerns about financial health.
Read more →PRLDPrelude Therapeutics to Participate in Citizens Life Sciences Conference
Prelude Therapeutics will participate in the Citizens Life Sciences Conference on May 7, 2025. CEO Kris Vaddi, CMO Jane Huang, and CSO Peggy Scherle will engage in a fireside chat. A live webcast will be available on the company's website, with an archived recording accessible for 90 days. Prelude is dedicated to developing innovative oncology therapies.
Read more →PRLDPrelude Announces Presentations at 2025 AACR Annual Meeting
Prelude Therapeutics announced new preclinical data presentations at the AACR Annual Meeting, highlighting their first-in-class SMARCA2 degrader PRT3789 and selective KAT6A degraders. The data suggest robust anti-cancer activity in preclinical models, particularly for breast cancer and solid tumors. The company aims to address safety challenges associated with non-selective approaches in oncology.
Read more →PRLDElucidating the Molecular Mechanism of Action of the First-in-Human SMARCA2 Selective Degrader PRT3789
The article discusses the introduction of PRT3789, the first-in-human SMARCA2 selective degrader. This innovative compound aims to enhance targeted therapies by elucidating its molecular mechanism of action. The study highlights the potential benefits of PRT3789 in clinical applications, marking a significant step forward in biopharmaceutical research.
Read more →PRLDDiscovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate anti-cancer activity in pre-clinical models
The article discusses the discovery of novel oral degraders targeting KAT6A, which have shown promising anti-cancer effects in pre-clinical studies. This first-in-class approach could pave the way for new cancer therapies. The findings highlight the potential of these degraders in addressing unmet medical needs in oncology.
Read more →PRLD▼ -9%on this news
PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Advanced Solid Tumors With a SMARCA4 Mutation: Phase 1 Trial
The article discusses a Phase 1 trial of PRT3789, an innovative intravenous SMARCA2 degrader, aimed at treating advanced solid tumors harboring a SMARCA4 mutation. This trial represents a significant step in targeting specific mutations in cancer therapy. The involvement of various experts highlights the collaborative effort in advancing this treatment.
Read more →PRLD▼ -9%on this newsshared move
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
Prelude Therapeutics has reported its financial results for the full year 2024, indicating strong advancements in its clinical programs, particularly focusing on SMARCA2 degraders like PRT3789. The company highlighted the promising safety and anti-tumor efficacy of PRT3789 in treating SMARCA4-deficient cancers. With a robust cash position of $133.6 million as of December 31, 2024, Prelude is well-funded to continue its research and development efforts well into the second quarter of 2026. Furthermore, the firm anticipates presenting additional results from ongoing clinical studies in the latter half of 2025.
Read more →PRLD▼ -9%on this newsshared move
PRELUDE THERAPEUTICS INCORPORATED BALANCE SHEETS December 31, (in thousands, except share and per share data) 2024 2023 Assets Current assets: Cash and cash equivalents $ 12,474 $ 25,291 Marketable securities 121,140 207
Prelude Therapeutics reported its financial results for the full year 2024, highlighting progress in the development of its SMARCA2 degrader therapy, PRT3789. The company demonstrated clinical proof-of-concept for PRT3789, which shows safety and anti-tumor activity in patients with SMARCA4-deficient cancers. Enrollment for dose escalation studies is nearing completion, and preliminary results are expected to be shared in 2025. Amidst the financial updates, Prelude has a strong cash position, projected to sustain operations through mid-2026.
Read more →PRLDPrelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
Prelude Therapeutics announced its participation in the Barclays 27th Annual Global Healthcare Conference set for March 11, 2025, in Miami, FL. Company leadership, including the CEO, President, and CFO, will conduct a fireside chat that will be available via live webcast. Prelude is recognized for its precision oncology efforts, developing innovative medicines aimed at addressing significant unmet needs in cancer treatment. The company is focused on creating advanced therapies, including unique degraders and antibody conjugates.
Read more →PRLDPrelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
Prelude Therapeutics has presented preliminary results from a Phase 1 dose-escalation study of PRT2527, a selective CDK9 inhibitor, indicating efficacy in patients with relapsed or refractory lymphoid malignancies. The study showed an overall response rate of 38.5% when combined with zanubrutinib. Despite demonstrating good tolerability, some patients suffered notable adverse effects, including neutropenia. Prelude is considering seeking a partner for further development of PRT2527 in hematologic malignancies.
Read more →PRLDInvestor Contact: Robert A. Doody Jr. Senior Vice President, Investor Relations 484.639.7235 rdoody@preludetx.com
Prelude Therapeutics presented preliminary results from its Phase 1 dose-escalation study of PRT2527, a selective CDK9 inhibitor for treating relapsed/refractory lymphoid malignancies, at the 66th American Society of Hematology Annual Meeting. The data showed that PRT2527 is generally well-tolerated and yielded a 38.5% overall response rate when combined with zanubrutinib. Prelude plans to seek a partner for further development of PRT2527 in hematologic malignancies. The trial continues to evaluate the efficacy and safety of the drug in this patient population.
Read more →PRLD▼ -5.8%on this news· ran to -22% by day 3shared move
Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Cancer Cell Death in Preclinical Models of Acute Myeloid Leukemia
The study highlights the potential of selective SMARCA2 degradation in promoting leukemic differentiation and enhancing the efficacy of CDK9 inhibition. This combination shows a strong ability to induce cancer cell death in preclinical models of acute myeloid leukemia, indicating a promising therapeutic strategy. The findings could lead to new treatment options for patients with this aggressive cancer.
Read more →PRLD▼ -5.8%on this news· ran to -22% by day 3shared move
Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, In Patients With Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies
The article discusses a Phase Ib study of PRT543, an oral PRMT5 inhibitor, aimed at patients with relapsed or refractory myeloid malignancies characterized by splicing factor mutations. The study involves a team of researchers and highlights the potential of PRT543 to address unmet medical needs in this patient population.
Read more →PRLD▼ -5.8%on this news· ran to -22% by day 3shared move
Preliminary Results of a Phase 1, Dose‑Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed / Refractory Lymphoid Malignancies
The article discusses preliminary results from a Phase 1 dose-escalation study of PRT2527, a selective CDK9 inhibitor. The study evaluates PRT2527 both as a monotherapy and in combination with Zanubrutinib in patients with relapsed or refractory lymphoid malignancies. Early findings suggest potential benefits in treatment efficacy, warranting further investigation.
Read more →PRLD▲ +7.1%on this news
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
Prelude Therapeutics announced its participation in the Citizens JMP Securities Hematology and Oncology Summit on December 2, 2024. CEO Kris Vaddi and CMO Jane Huang will engage in a fireside chat during the virtual event. The chat will be accessible via a live webcast and subsequently archived for 90 days on the company's website. Prelude is recognized for its commitment to precision oncology and is developing various novel drug candidates.
Read more →PRLDIdentification of triazolyl KAT6 inhibitors via a templated fragment approach
The article discusses the identification of triazolyl KAT6 inhibitors using a templated fragment approach. This research is part of Prelude Therapeutics' ongoing efforts to develop targeted therapies. The study highlights the potential of these inhibitors in precision medicine, particularly for conditions associated with KAT6A.
Read more →PRLDDiscovery of first-in-class precision antibody drug conjugates with a potent SMARCA2/4 dual degrader payload
The article discusses the discovery of a novel class of precision antibody drug conjugates featuring a powerful SMARCA2/4 dual degrader payload. This advancement is expected to enhance the effectiveness of targeted cancer treatments. The research highlights the innovative approach taken by the team to develop these conjugates.
Read more →PRLDPrelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Prelude Therapeutics reported its financial results for Q3 2024, highlighting significant advancements in its clinical pipeline. The company presented interim data showing clinical proof of concept for its intravenous SMARCA2 degrader, PRT3789, which treats aggressive SMARCA4-mutated cancers. Additionally, Prelude initiated a Phase 1 trial for its oral SMARCA2 degrader, PRT7732, and reported a solid financial position with $153.6 million in cash. The company is focused on further progress in its lead clinical programs and plans to disclose updates in early 2025.
Read more →PRLD▼ -5.5%on this news
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
Prelude Therapeutics has presented new data from its ongoing trial of PRT3789, a SMARCA2 degrader for cancer patients with SMARCA4 mutations, at the 36th EORTC-NCI-AACR Symposium. Interim results from 65 patients indicate that higher doses produce deeper SMARCA2 degradation with confirmed partial responses in a subset of patients with advanced NSCLC. Safety data from combination studies with docetaxel show an acceptable profile, while additional preclinical data suggest strong efficacy for a novel antibody drug conjugate program. The company continues its Phase 1 trial with an ongoing focus on dose escalation.
Read more →PRLD▼ -5.5%on this news
undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.   Investor Contact: Robert A. Doody Jr. Senio
Prelude Therapeutics has presented promising interim results from its Phase 1 trial of PRT3789, a selective SMARCA2 degrader aimed at patients with SMARCA4 mutations. The data indicates increased clinical activity at higher doses and an acceptable safety profile from the combination study with docetaxel. Additionally, preclinical data on their novel antibody drug conjugate approach shows potential efficacy against multiple cancers. The company continues to enroll patients for further investigation into the drug's effectiveness and safety.
Read more →PRLDClinical results from a phase 1 trial of PRT3789, a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation
The article discusses the clinical results from a Phase 1 trial of PRT3789, a novel intravenous SMARCA2 degrader. This treatment is aimed at patients with advanced solid tumors harboring a SMARCA4 mutation. The trial's findings suggest that PRT3789 could offer a new therapeutic avenue for this patient population.
Read more →PRLD▼ -6.3%on this newsshared move
The Selective SMARCA2 Degrader, PRT3789, Counteracts the Protective Cellular Stress Response to Chemotherapy and Enhances the Efficacy of Standard of Care Chemotherapeutic Agents in SMARCA4 Mutant NSCLC Models
The article discusses PRT3789, a selective SMARCA2 degrader, which has been shown to counteract the protective cellular stress response to chemotherapy. This compound enhances the efficacy of standard chemotherapeutic agents in models of non-small cell lung cancer (NSCLC) with SMARCA4 mutations. The findings suggest a potential new avenue for improving treatment outcomes in affected patients.
Read more →PRLD▼ -5.2%on this newsshared move
Discovery of first-in-class precision antibody drug conjugates with a potent SMARCA2/4 dual degrader payload that safely achieve maximal and tumor specific degradation and efficacy in mouse models
The article discusses the development of a novel class of precision antibody drug conjugates that utilize a dual degrader payload targeting SMARCA2/4. These conjugates have shown the ability to achieve maximal and tumor-specific degradation, demonstrating significant efficacy in preclinical mouse models. This advancement may lead to improved therapeutic options in cancer treatment.
Read more →PRLD▼ -6.9%on this news
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
Prelude Therapeutics announced the publication of three abstracts for its SMARCA Degrader Programs, set to be presented at the 36th EORTC-NCI-AACR Symposium in Barcelona from October 23-25, 2024. The insights include updates from the Phase 1 clinical trial of the SMARCA2 degrader PRT3789 and the debut of data on precision antibody drug conjugates. The company expects to complete dose escalation by the end of 2024 and is engaging with regulatory agencies for future trial discussions. Their approach aims to address high unmet medical needs in oncology.
Read more →PRLD▼ -42.7%on this news
First clinical results from a phase 1 trial of PRT3789, a first-in-class SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation
The article discusses the first clinical results from a Phase 1 trial of PRT3789, a novel SMARCA2 degrader, in patients with advanced solid tumors harboring a SMARCA4 mutation. The trial aims to evaluate the safety and efficacy of this innovative treatment approach. Early results suggest potential benefits for patients with this specific mutation.
Read more →PRLD▼ -42.7%on this newsshared move
Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial - Encouraging signs of anti-tumor activity including objective responses observed in pat
Prelude Therapeutics announced positive interim results from its Phase 1 trial of PRT3789, a first-in-class SMARCA2 degrader targeting cancers with SMARCA4 mutations. Encouraging signs of efficacy were observed, with tumor shrinkage reported in some patients with NSCLC and esophageal cancer. The drug exhibited a favorable safety profile, having no dose-limiting toxicities or serious adverse events. Continued dosage escalation is underway, and further data is expected as the trial progresses.
Read more →PRLDPrelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
Prelude Therapeutics has announced the publication of an abstract that will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2024. This event is significant for the company as it showcases their research and developments in oncology. The presentation is expected to attract attention from industry professionals and stakeholders.
Read more →PRLDPrelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024 PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid
Prelude Therapeutics announced the upcoming presentation of clinical data on PRT3789, a novel SMARCA2 degrader, at the ESMO Congress 2024. The drug is in Phase 1 trials for patients with advanced solid tumors who have a SMARCA4 mutation. Initial results show promising safety, tolerability, and signs of effectiveness, including partial responses and prolonged stable disease in difficult-to-treat cancer cases. The company will provide updated data during the congress, highlighting the importance of this therapy in addressing unmet medical needs in oncology.
Read more →PRLD▼ -6.9%on this news· ran to +22% by day 1
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Prelude Therapeutics announced its second-quarter 2024 financial results, highlighting key developments in its clinical pipeline. The company received IND authorization for its oral SMARCA2 degrader, PRT7732, and is collaborating with Merck to evaluate PRT3789 in combination with KEYTRUDA in patients with SMARCA4-mutated cancers. Prelude also continues to advance their other lead candidate, PRT2527, with interim clinical data expected later this year. Despite a reported net loss of $34.7 million for the quarter, the company possesses a solid cash position to fund operations into 2026.
Read more →PRLDPrelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
Prelude Therapeutics has announced a clinical collaboration with Merck to evaluate its investigational drug PRT3789, a highly selective SMARCA2 degrader, in combination with Merck's anti-PD-1 therapy KEYTRUDA in patients with SMARCA4-mutated cancers. This Phase 2 clinical study aims to leverage the complementary mechanisms of both agents to improve treatment outcomes. Prelude is sponsoring the trial while Merck provides KEYTRUDA, retaining commercial rights for both products. The collaboration is expected to bring innovative treatment options to patients with limited choices.
Read more →PRLDCorporate Presentation June 2024 Forward Looking Statements This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities
Prelude has outlined its strategic priorities for June 2024, focusing on advancing their precision oncology product candidates, particularly SMARCA2 degrader molecules. The company aims to generate proof-of-concept data and expand its clinical pipeline targeting specific oncogenic mechanisms while continuing to build leadership in SMARCA research. The presentation also emphasizes the importance of their experienced leadership team in driving innovation within the company. However, it notes that certain data presented are based on limited comparisons and that forward-looking statements are subject to inherent uncertainties.
Read more →PRLD▲ +13.4%on this news
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
Prelude Therapeutics announced its participation in the upcoming Citizens JMP Life Sciences Conference in New York City on May 13 and 14, 2024. CEO Kris Vaddi and CMO Jane Huang will conduct a fireside chat on May 14. The discussion will be accessible via a live webcast and archived on Prelude's website for later viewing. Prelude is recognized for its clinical-stage precision oncology initiatives and has several innovative drug candidates in its pipeline.
Read more →PRLDPRELUDE THERAPEUTICS INCORPORATED BALANCE SHEETS (UNAUDITED) (in thousands, except share data)
Prelude Therapeutics Incorporated reported its financial results for the first quarter of 2024, indicating progress in its clinical development pipeline. The company remains on track to present initial proof-of-concept data for its lead drug candidates, PRT3789 and PRT2527, later this year. With a strong cash position anticipated to last until 2026, Prelude is effectively advancing its promising oncology-focused initiatives. The appointment of new executives is expected to bolster the company's operational capabilities, although it also reported a net loss for the quarter.
Read more →PRLDPrelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Prelude Therapeutics Inc. reported its Q1 2024 financial results and updated on its clinical development pipeline. CEO Kris Vaddi highlighted progress on their lead drug candidates, PRT3789 and PRT2527, both on track to deliver proof-of-concept data later in 2024. The company has strengthened its leadership with new appointments and has a substantial cash reserve of $201.9 million to support operations until 2026. Despite an increase in R&D expenditures and a growing net loss, Prelude remains optimistic about its clinical trajectory.
Read more →PRLD▼ -14.9%on this news· ran to -30% by day 1
The Brain Penetrant CDK4/6 Inhibitor, PRT3645, is Highly Effective in Combination with Other Targeted Therapies in Preclinical Models of Breast Cancer, CRC and NSCLC
The article discusses the effectiveness of PRT3645, a brain-penetrant CDK4/6 inhibitor, in combination with other targeted therapies. Preclinical models of breast cancer, colorectal cancer (CRC), and non-small cell lung cancer (NSCLC) show significant promise. This combination approach may enhance treatment efficacy for these cancers.
Read more →PRLD▼ -14.9%on this news· ran to -30% by day 1shared move
Preclinical Characterization of PRT7732: A Highly Potent, Selective, and Orally Bioavailable Targeted Protein Degrader of SMARCA2
The article discusses the preclinical characterization of PRT7732, a targeted protein degrader of SMARCA2. Researchers highlight its high potency, selectivity, and oral bioavailability, suggesting its potential as a therapeutic agent. The findings indicate promising avenues for further development in targeted therapies.
Read more →PRLD▼ -14.9%on this news· ran to -30% by day 1shared move
PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor,Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid Malignancies
PRT2527, a selective CDK9 inhibitor, demonstrates significant antitumor effects when used in combination with BTK and BCL2 inhibitors. This combination therapy shows potential for treating various lymphoid malignancies, suggesting a new avenue for effective cancer treatment. The findings highlight the importance of targeting CDK9 in cancer therapy.
Read more →PRLD▲ +6.2%on this news· ran to +20% by day 3
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Prelude Therapeutics presented promising preclinical data at the AACR Annual Meeting, highlighting their drug candidates PRT7732, PRT2527, and PRT3645. PRT7732, an oral SMARCA2 degrader, shows strong anti-tumor activity and is set to enter clinical trials in late 2024. PRT2527 has shown potent effects against several lymphoid malignancies, while PRT3645 is effective when combined with other therapies for breast cancer and other indications. The advancements signify Prelude's commitment to developing innovative cancer treatments.
Read more →PRLDPrelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Prelude Therapeutics has announced that three of its preclinical abstracts have been accepted for presentation at the AACR Annual Meeting 2024. Highlights include the presentation of data on the SMARCA2 degrader PRT7732, which is slated for Phase 1 development later this year. The company will also present findings on the CDK9 inhibitor PRT2527 and the next-generation CDK4/6 inhibitor PRT3645, emphasizing their therapeutic value in various cancers. Additionally, Prelude is hosting a live webcast to discuss the science behind SMARCA2's clinical relevance.
Read more →PRLDPrelude Therapeutics to Participate in Barclays Global Healthcare Conference
Prelude Therapeutics announced its participation in the Barclays Global Healthcare Conference scheduled for March 12-14, 2024. CEO Kris Vaddi and CMO Jane Huang will engage in a fireside chat on March 13, sharing insights into the company's projects and innovations. The event highlights Prelude's ongoing commitment to advancing its pipeline of precision oncology candidates.
Read more →PRLD▼ -10.2%on this news
PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer
The article discusses the association between PBRM1 loss and increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer. This discovery suggests that patients with PBRM1 loss may benefit from targeted therapies that inhibit these proteins. The findings could pave the way for more effective treatment strategies tailored to genetic profiles.
Read more →PRLDPrelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024 First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-c
Prelude Therapeutics reported its financial results for the year ended December 31, 2023, highlighting the advancement of its pipeline, including a first-in-class IV SMARCA2 degrader and a CDK9 inhibitor, both on track for proof-of-concept data in 2024. The company has established a partnership with AbCellera to develop next-generation precision ADCs, alongside maintaining a healthy cash position expected to support operations until 2026. Despite a net loss and rising R&D expenses, Prelude remains focused on delivering innovative therapies for underserved cancer patients.
Read more →PRLDPRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study
The article discusses a phase I dose-expansion study of PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma. The study aims to evaluate the safety and efficacy of this novel treatment. The involvement of a diverse group of researchers highlights the collaborative effort in advancing cancer therapies.
Read more →PRLDPrelude Therapeutics Announces $25 Million Private Placement WILMINGTON, DE
Prelude Therapeutics has announced a private placement expected to generate approximately $25 million to fund its SMARCA2 portfolio and general corporate purposes. The company projects that current cash combined with proceeds from this placement will sustain operations through 2026. CEO Dr. Kris Vaddi highlighted plans to rigorously advance the clinical development of the IV molecule PRT3789 and initiate clinical development for an oral program in the latter half of 2024. The closing of the placement is anticipated on or around December 13, 2023, pending customary conditions.
Read more →PRLD▲ +10.1%on this news· ran to +75% by day 3
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Prelude Therapeutics and AbCellera have initiated a multi-year partnership to co-develop precision antibody drug conjugates (ADCs) for cancer treatment. This collaboration leverages Prelude's strengths in targeted protein degradation and clinical development alongside AbCellera's advanced antibody discovery capabilities. The first program aims to extend the applicability of Prelude's small molecule SMARCA2 selective degraders to a broader patient demographic. Under the agreement, both companies will jointly manage various aspects of product discovery and commercialization, with specific roles assigned to each.
Read more →PRLD▲ +10.1%on this news· ran to +75% by day 3
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results Prioritization of its first-in-class SMARCA2 degrader and potentially best-
Prelude Therapeutics has announced strategic updates regarding their clinical pipeline, highlighting the prioritization of their SMARCA2 degrader and CDK9 inhibitor programs. They reported a solid cash position, enabling operations through 2026, and formed a partnership with AbCellera for developing precision antibody-drug conjugates (ADCs). The company is optimistic about achieving initial clinical proof-of-concept for both lead programs in 2024. However, they will not be advancing some programs, which presents limitations on treatment options for certain cancers.
Read more →PRLD▼ -10.5%on this news
A Phase 1 Study of PRT3789, a Potent and Selective Degrader of SMARCA2 in Patients with Advanced or Metastatic Solid Tumors and a SMARCA4 Mutation
The article discusses a Phase 1 study of PRT3789, a selective degrader targeting SMARCA2 in patients with advanced or metastatic solid tumors possessing a SMARCA4 mutation. The study aims to evaluate the safety and efficacy of this novel therapeutic approach. A team of notable researchers is involved in this clinical trial.
Read more →PRLDClinical Biomarkers Based on PK/PD Modeling to Guide the Development for a First-in-Class, Highly Selective SMARCA2 (BRM) Degrader, PRT3789
The article discusses the development of PRT3789, a first-in-class SMARCA2 (BRM) degrader. It highlights the importance of clinical biomarkers based on pharmacokinetic/pharmacodynamic (PK/PD) modeling in guiding its development. The focus is on the scientific and strategic aspects of the drug's progression within Prelude Therapeutics' pipeline.
Read more →PRLDDiscovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers
Prelude Therapeutics has announced the discovery of PRT3789, a first-in-class SMARCA2 degrader. This innovative drug is currently in clinical trials aimed at treating patients with cancers that have SMARCA4 mutations. The development showcases the commitment of the Prelude Therapeutics team to advancing targeted therapies in oncology.
Read more →PRLDA Phase 1 Open-Label, Dose-Escalation Study of Central Nervous System-Penetrant Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PRT3645, in Patients With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics has announced the initiation of a Phase 1 open-label, dose-escalation study for PRT3645, a central nervous system-penetrant CDK4/6 inhibitor. This study aims to evaluate the drug's safety and efficacy in patients with select advanced or metastatic solid tumors. The development reflects Prelude's commitment to addressing significant challenges in cancer treatment.
Read more →PRLDA Phase 1, Open-Label, Dose-Escalation Study of a CDK9 Inhibitor, PRT2527, in Adult Patients With Advanced Solid Tumors: An Updated Analysis
The article discusses a Phase 1, open-label, dose-escalation study of PRT2527, a CDK9 inhibitor, in adult patients with advanced solid tumors. This updated analysis includes contributions from multiple experts in the field, highlighting the potential of PRT2527 in oncology. The study aims to evaluate the safety and efficacy of the drug in a challenging patient population.
Read more →PRLDPRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies
The article discusses the role of PRMT5 inhibitors in regulating DNA damage repair pathways in cancer cells. It highlights their potential to improve responses to PARP inhibitors and chemotherapies. This research suggests that targeting PRMT5 could enhance treatment efficacy for cancer patients, offering a new avenue for therapeutic strategies.
Read more →PRLDPrelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
Prelude Therapeutics has announced multiple poster presentations at the AACR-NCI-EORTC International Conference, showcasing data from ongoing clinical trials for its CDK9 inhibitor PRT2527 and CDK4/6 inhibitor PRT3645, along with preclinical findings for the SMARCA2 degrader compound PRT3789. Initial data from trials indicates efficacy and safety, prompting further development of these novel therapies. The company is optimistic about upcoming clinical readouts, particularly with PRT3789, which has shown synergy in preclinical models with other treatments.
Read more →PRLDPrelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
Prelude Therapeutics announced its participation in three upcoming healthcare investment conferences in September. Key executives, including CEO Dr. Kris Vaddi and CMO Dr. Jane Huang, will lead discussions and host one-on-one meetings with investors at these events. Their engagements are expected to enhance the company's visibility in the precision oncology sector and promote its diverse pipeline of promising drug candidates.
Read more →PRLDPrelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update Four lead programs on track to deliver clinical data and to inform future development plans. Recent equity financing exte
Prelude Therapeutics reported its second quarter 2023 financial results, highlighting critical advancements in its oncology pipeline with four lead programs on track for data delivery. The company completed a public offering, boosting its cash runway into 2026, which facilitates ongoing development. Noteworthy progress includes the recruitment for clinical trials of its candidates PRT2527 and PRT1419, showcasing their potential as best-in-class therapies. Despite a reported net loss of $30.4 million, the outlook remains optimistic as they approach significant milestones in their clinical research.
Read more →PRLDForward Looking Statements This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, i
Prelude Therapeutics presented forward-looking statements regarding its plans to develop and commercialize various small molecule therapies for cancer, including PRT1419, PRT2527, PRT3645, and others. The company emphasized its differentiated approach in creating therapies with potentially best-in-class selectivity and minimal off-target toxicity. Although these claims are hopeful, they caution that these forward-looking statements carry uncertainties and are dependent on the successful completion of clinical studies and regulatory approvals. The company aims to drive its programs toward key milestones, presenting initial clinical data in the second half of the year.
Read more →PRLDPrelude Therapeutics To Participate in Jefferies Healthcare Conference
Prelude Therapeutics Incorporated will participate in the Jefferies Healthcare Conference from June 7 to 9, 2023, in New York City. CEO Kris Vaddi will feature in a fireside chat on June 7, alongside key executives for one-on-one meetings. The company is focused on developing precision oncology drug candidates that target critical cancer cell pathways and has an active pipeline with four clinical candidates.
Read more →PRLD▼ -11.4%on this news
Prelude Therapeutics Announces Pricing of Public Offering
Prelude Therapeutics has announced the pricing of a public offering, consisting of over 3 million shares of voting and non-voting common stock. The offering is expected to raise approximately $100 million, which will support the company's diverse pipeline of oncology drug candidates. The closing of the offering is anticipated on or around May 22, 2023, pending customary closing conditions. Morgan Stanley is serving as the sole book-running manager for this offering, which has generated positive sentiment due to its potential financial boost for the company.
Read more →PRLDPrelude Therapeutics Announces Launch of Proposed Public Offering WILMINGTON, Del. (Globe Newswire)
Prelude Therapeutics has announced a public offering of $100 million in common stock and pre-funded warrants to support its clinical pipeline and research efforts. The offering, led by Morgan Stanley, includes a 30-day option for underwriters to purchase additional shares. Funds raised will be allocated to develop specific drug candidates and general corporate purposes. However, the completion of the offering is subject to market conditions, which adds uncertainty to the timing and expected proceeds.
Read more →PRLDForward Looking Statements This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to
The corporate presentation by Prelude Therapeutics discusses forward-looking statements regarding its oncology pipeline, including the development and commercialization of several small molecule therapies such as PRT1419, PRT2527, and PRT3645. The company expresses confidence in its ability to complete clinical studies and regulatory approvals, but also acknowledges substantial uncertainties and risks inherent in these projections. The presentation highlights potential advancements in treating various cancers while providing a cautiously optimistic outlook on upcoming clinical milestones.
Read more →PRLDPrelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the
Prelude Therapeutics reported Q1 2023 financial results and highlighted the progress made in its pipeline during the AACR 2023. Eight abstracts showcased advancements, with particular focus on PRT2527 and PRT1419, both showing encouraging safety profiles. Prelude's financial standing remains strong with cash reserves projected to last until Q4 2024, despite a net loss recorded for the quarter. The company continues its commitment to address unmet needs in cancer treatment through its innovative therapies.
Read more →PRLDPrelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
Prelude Therapeutics has announced its participation in three healthcare investor conferences in May. The company's CEO and other executives will engage in discussions and one-on-one meetings with investors at these events. The mentioned conferences include the H. C. Wainwright BioConnect, Bank of America Securities, and JMP Securities Life Sciences Conferences. Prelude is focused on developing precision oncology treatments and showcasing its diverse pipeline of drug candidates.
Read more →PRLD▲ +9%on this news
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Prelude Therapeutics announced its participation in the AACR Annual Meeting 2023, where it will present eight abstracts, including clinical data on PRT2527 and PRT1419. These presentations underscore progress in developing therapies for hematological cancers and introduce preclinical data on novel compounds, such as SMARCA2 degraders. This conference marks a pivotal moment for Prelude as they seek to advance their promising oncology pipeline.
Read more →PRLD▲ +8.5%on this news
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
Prelude Therapeutics has announced a clinical trial collaboration with BeiGene to evaluate PRT2527, an investigational CDK9 inhibitor, in combination with BeiGene's BTK inhibitor, zanubrutinib, for treating hematologic cancers. The combination is based on recent evidence suggesting synergistic clinical efficacy. Under the terms of the agreement, BeiGene will provide zanubrutinib, while Prelude retains rights for PRT2527's global development and commercialization. This collaboration is expected to enhance treatment options for patients with certain B cell malignancies.
Read more →PRLD▲ +8.5%on this news
Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for pres
Prelude Therapeutics has reported its financial results for the fiscal year 2022, highlighting significant progress in developing four clinical compounds targeting key cancer pathways. As of December 31, 2022, the company had a solid cash position of $201.7 million, ensuring operational continuity through at least Q4 2024. Positive preliminary data for its lead compounds PRT2527 and PRT1419 support their further development. The company has also accepted eight abstracts for presentation at the 2023 AACR Annual Meeting, reflecting ongoing research advancements and collaborations.
Read more →PRLDPrelude Therapeutics To Participate in Barclays Global Healthcare Conference
Prelude Therapeutics Incorporated announced its participation in the Barclays Global Healthcare Conference scheduled for March 14-16, 2023. CEO Kris Vaddi and President Jane Huang will take part in a fireside chat and host one-on-one meetings during the event. Prelude is developing innovative drugs targeting critical cancer pathways and has a diverse pipeline, including several promising candidates currently in clinical development.
Read more →PRLDPrelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
Prelude Therapeutics, a clinical-stage precision oncology company, announced its participation in three healthcare investment conferences in February 2023. Key executives will present at the SVB Securities Global Biopharma Conference and the Wells Fargo Targeted Protein Degradation Summit, discussing important topics in oncology. Prelude's ongoing development includes a pipeline of potentially best-in-class small molecule compounds targeting critical cancer pathways.
Read more →PRLD▼ -8.8%on this news
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhi
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor) Company to reprioritize clinical pipeline and disco
Read more →PRLDPrelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
WILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration, (FDA) cleared the company to proceed with a Phase 1 study under
Read more →PRLD▼ -5.5%on this news
Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences
WILMINGTON, Del., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be participating in two healthcare investment conferences next week in New York City
Read more →PRLDPrelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update Prelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Admin
Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update Prelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Administration (FDA) Clinical data readouts and next steps for
Read more →PRLD▲ +9.5%on this news
Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibit
Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $
Read more →PRLD▲ +8.4%on this news
Prelude Therapeutics Reports Full Year 2021 Financial Results Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in can
Prelude Therapeutics Reports Full Year 2021 Financial Results Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients Objectives for 2022: Focuse
Read more →PRLDPrelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference
WILMINGTON, Del., March 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the Barclays 2022 Global Healthcare Co
Read more →PRLD▲ +7.5%on this newsshared move
Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting
Announces strategic prioritization within lead programs targeting PRMT5 and MCL1 Describes new pipeline candidate, PRT3645, a highly brain penetrant CDK4/6 inhibitor; IND submission planned mid-2022 Advances PRT2527, a highly selective CDK9 inhibitor, with the goal of establis
Read more →PRLD▲ +7.5%on this newsshared move
Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer Wilmington, DE
Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer Wilmington, DE March 9, 2022 Prelude Therapeutics Incorporated (Nasdaq: PRLD) a clinical-stage precision oncology company, today announced that Jane Huang, M.D., has been appointed to the newly
Read more →PRLDPrecision Oncology Redefined February 2022 Forward-Looking Statements This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
Forward-Looking Statements This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our plans to develop and commercialize small molecule th
Read more →PRLDPrelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
WILMINGTON, Del., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Confer
Read more →PRLD▼ -13.5%on this news· ran to -24% by day 3
Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the H.C Wainwright BioConnect Virtual Conference, being held o
Read more →PRLD▲ +5.5%on this news
Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference
WILMINGTON, Del., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx
Read more →PRLDPrelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose
Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients Phase 1 Dose Expansion
Read more →PRLDPrelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor
WILMINGTON, Del., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for its
Read more →PRLD▼ -39.7%on this news
Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
– Lead oral PRMT5 inhibitors PRT543 and PRT811 demonstrate favorable safety profile, evidence of preliminary clinical activity including durable responses and high levels of target inhibition of PRMT5 in Phase 1 dose escalation in unselected patients – – CDK9 inhibitor PRT2527 d
Read more →PRLDPrelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences
WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: Morgan Stanley 19th Annu
Read more →PRLDPrelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update - Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors PRT543 and PRT811 to be Presented in 4Q21 - -
Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update - Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors PRT543 and PRT811 to be Presented in 4Q21 - - Enrollment Ongoing in Multiple Expansion Cohorts in Phas
Read more →PRLD▲ +10.5%on this news
Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors
WILMINGTON, Del., July 19, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Martin Babler to its Board of Directors. Mr. Babler brings to Prelude over 25 years of pharmaceutical and
Read more →PRLDDisclaimer This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our plans to d
Corporate Presentation May 2021 Exhibit Disclaimer This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our plans to develop and commerc
Read more →PRLDPrelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update - Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhi
Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update - Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead O
Read more →PRLDPrelude Therapeutics Announces Presentation at BofA Securities 2021 Virtual Health Care Conference
WILMINGTON, Del., May 05, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the BofA Securities 202
Read more →PRLDPrelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update - Dose Escalation Portion of Phase 1 Trial of PRT543 Complete; Additional Expansion Cohorts Set to Initia
Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update - Dose Escalation Portion of Phase 1 Trial of PRT543 Complete; Additional Expansion Cohorts Set to Initiate Early in the Second Quarter - -Clinical Data Readouts E
Read more →PRLDPrelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences
WILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in three upcoming virtual inves
Read more →PRLDPrelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its upsized public offering of 2,583,334 shares of its voting common stoc
Read more →PRLDPrelude Therapeutics Announces Pricing of Upsized Public Offering
WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its upsized public offering of 2,208,3
Read more →PRLDPrelude Therapeutics Announces Launch of Proposed Public Offering
WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced a public offering of 1,750,000 shares of its common stock pursuant
Read more →PRLDCorporate January 2021 Presentation Disclaimer This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including
January 2021 Presentation Disclaimer This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our plans to develop and commercialize small m
Read more →PRLDPrelude Therapeutics Announces Third Quarter 2020 Financial Results - Completed Initial Public Offering of Common Stock, Raising Gross Proceeds of ~$181.9M million - - Partial Response Confirmed in Glioblastoma Multiform
Prelude Therapeutics Announces Third Quarter 2020 Financial Results - Completed Initial Public Offering of Common Stock, Raising Gross Proceeds of ~$181.9M million - - Partial Response Confirmed in Glioblastoma Multiforme Patient in Phase 1 Trial of PRT811 - - Durable Complete
Read more →PRLDPrelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies
WILMINGTON, Del., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the first patient has been dosed in its first-in-human Phase 1 open-label, multicenter, dose-escalation study o
Read more →PRLDPrelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
WILMINGTON, Del., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its initial public offering of 9,573,750 shares of common stock, including the full exercise of the u
Read more →PRLDPrelude Therapeutics Announces Pricing of Initial Public Offering
WILMINGTON, Del., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its initial public offering of 8,325,000 shares of its common stock at a public offering price of $19
Read more →Competitive Position
How PRLD ranks across every disease it competes inCompetitive Position is a premium feature
See how PRLD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial